On April 19, Oklahoma Governor Kevin Stitt (R) signed co-pay accumulator ban bill HB 2678 into law. This measure requires Pharmacy Benefit Managers (PBMs) to include any amount paid by an enrollee, or on behalf of an enrollee, when calculating the enrollee’s out of pocket maximum, copay, coinsurance, deductible, or cost sharing requirement. The Oklahoma […]
During this unprecedented time, Merck is committed to ensuring their medicines and vaccines reach their patients and customers. This includes supporting patients who might need more help today with their medications, including those who are unemployed or have lost insurance coverage due to the COVID-19 pandemic. To learn about what support options may be available, […]
Takeda Oncology announces that the name of their patient support program has changed from Takeda Oncology 1Point to Takeda Oncology Here2Assist™ effective May 18, 2020. Please note that only the name is changing. Patients and providers will continue to have the same high level of comprehensive, personalized support. Please review the important details regarding the change here: Takeda […]
Merck Sharp & Dohme Corp. (“Merck”), a subsidiary of Merck & Co., Inc., is pleased to announce that ONTRUZANT® (trastuzumab-dttb) for injection, for intravenous use 21 mg/mL, a biosimilar* to Herceptin® (trastuzumab), is available through specialty distributors and wholesalers. Please contact your specialty distributor or wholesaler to confirm product availability. Before prescribing ONTRUZANT, please read the Prescribing Information, including the […]
The US Food and Drug Administration recently approved REBLOZYL® (luspatercept-aamt), the first and only erythroid maturation agent (EMA) indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of […]
Released: November 14, 2019 The U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma usually responds well to initial treatment, but eventually returns or stops responding, and the cancer cells continue […]
Merck is pleased to announce the availability of a new pack for KEYTRUDA® (pembrolizumab)Injection 100 mg/4 mL (25 mg/mL) (“KEYTRUDA”).The new pack contains two 100mg/4 mL single-dose vials in a single carton. The price per vial of KEYTRUDA is not affected by the introduction of this new pack. The National Drug Code (NDC) for this […]
INREBIC® (fedratinib) capsules, a product from Celgene, is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INDICATION INREBIC® (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). IMPORTANT SAFETY […]
AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…
AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…
